Antibiotic Incentives Helped Spero Get Where It Is Today
The firm is developing a novel class of antibacterials that could enable shelved agents for Gram-positive infections to reach and kill Gram-negative bacteria.
You may also be interested in...
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
A year of Drug Review Profiles in the Pink Sheet shows how important the choice of regulatory pathway has become to drug development and approval.
A set of 19 bills aimed at improving the efficiency and pace at which the FDA and the National Institutes of Health (NIH) do their work is now on its way the full Senate for consideration after the chamber's Health, Education, Labor and Pensions (HELP) Committee agreed during an April 6 markup session on the remaining pieces of legislation.